drugset / Trial / NCT05759312
Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to evaluate the safety and effectiveness of zimberelimab combined with metformin in treating relapsed/persistent ovarian clear cell carcinoma.
Timeline
- Start
- 2023-03
- Primary completion
- 2025-02
- Completion
- 2025-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Metformin | Small molecule | 2000 mg | Oral |
| Subject | Zimberelimab | Monoclonal antibody | 240 mg | Intravenous |